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Introduction
Palmoplantar psoriasis is plaque psoriasis involving 
the palms and soles. Studies have shown that up to 
40 percent of patients with plaque psoriasis have 
some form of palmoplantar involvement, appearing 
previously or during their plaque psoriasis course 
[1]. Owing to its location and manifestations, 
palmoplantar psoriasis is associated with greater pain, 
functional limitations, and significant impairment of 
health-related quality of life.
Palmoplantar psoriasis is a treatment challenge for 
dermatologists and it is difficult to treat with topical 
and systemic therapies. Treatments that achieve 
a good response in other parts of the body may 
perform poorly in palmoplantar regions. However, 
some biologic agents have shown partial and total 
responses in this type of psoriasis. There are a few 
trials studying the effect of systemic therapies on 
palmoplantar psoriasis.
Recently a new biologic agent, secukinumab, has 
been approved for treatment of moderate to severe 
plaque psoriasis. Secukinumab is a fully human 
monoclonal immunoglobulin G1κ antibody targeting 
human interleukin-17A, an important cytokine in the 
pathogenesis of psoriasis [2].
In the Summary of Product Characteristics of 
the European Medicines Agency, the efficacy of 
secukinumab in palmoplantar psoriasis is noted 
[2]. GESTURE study is a double-blind, randomized, 
placebo-controlled, parallel-group multicenter phase 
3b study that evaluated the efficacy of secukinumab 
in palmoplantar psoriasis. One-third of patients 
receiving secukinumab 300mg achieved clear or 
almost clear palms and soles at week 16 [2,4].
Case Synopsis
A 63-year-old man with a 15-year history of psoriasis 
vulgaris with palmar involvement presented in 
our dermatology clinic. He had no family history 
of psoriasis and did not have psoriatic arthritis. 
He weighed 90kg and had metabolic syndrome, 
managed with antihypertensive medication.
Palmar involvement had not responded adequately 
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to topical treatment, classic systemic therapies 
(methotrexate and acitretin), and ustekinumab 45mg 
for 30 months, even after the addition of acitretin 
for 6 months. After the last treatment combination, 
most lesions of plaque psoriasis showed significant 
resolution of trunk, gluteal folds, and groin psoriasis, 
achieving PGA 1 in these regions. However, the palms 
showed significant erythema, thickness, scaling, and 
fissures (ppPGA 5).
The patient was an artist (painter). His palmar 
involvement resulted in functional limitations. He 
was not able to work, which had a high negative 
impact on quality of life DLQI 7 (Figure 1a).
Treatment with secukinumab 300mg (monotherapy) 
was started in March, 2016. After one month, fifty 
percent of psoriatic plaque was cleared, resulting in 
ppPGA 3 (Figure 1b). Continued improvement was 
observed thereafter at week 12 (Figure 1c) and week 
44 (Figure 1d), achieving a ppPGA 0/1. The patient 
has returned to work, without any limitation. No 
adverse events have been observed throughout the 
course of treatment.
Case Discussion
In an open-label trial of ustekinumab for palmoplantar 
psoriasis with 20 patients (50% of patients with 
pustules and ppPGA ≥ 3 at baseline), 35% of subjects 
achieved ppPGA 0/1 at week 16 with ustekinumab. 
Sixty-seven percent of those receiving ustekinumab 
90mg achieved clinical clearance compared with 
nine percent receiving 45 mg [3]. However, our 
patient did not achieve an acceptable response with 
ustekinumab.
Our patient has had ongoing treatment with 
secukinumab for 30 weeks and is still clear. This 
Figure 1. A) Palms of the patient at baseline; B-D) and at weeks 4, 12 and 44 of treatment with secukinumab, respectively.
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experience corroborates the GESTURE study results 
as well as the Phase II subanalysis of secukinumab. 
[4-6].
Palmoplantar psoriasis is a difficult-to-treat 
presentation. Therapies that achieve good responses 
in other parts of the body often do not have the 
same effectiveness in the palmoplantar regions. 
Furthermore, patients with palmoplantar psoriasis 
suffer discomfort and disability. According to the 
Spanish Evidence-Based Guidelines, systemic 
treatments should be used with this subpopulation 
of patients with functional impairment [7].
There is limited data exist regarding the genes 
involved in palmoplantar psoriasis compared 
to psoriasis vulgaris. Future genetic and clinical 
investigation will be essential to clarify if genetic 
basis may influence the response to therapy [8].
Secukinumab has shown promising results in the 
treatment of palmoplantar psoriasis. Interleukin-17 
inhibition may play an important role in this 
localized form of psoriasis. Further knowledge of the 
pathophysiologic pathways is needed to better treat 
our patients and improve their quality of life.
Conclusion
We report the successful use of secukinumab in 
palmar psoriasis, a special location difficult to treat 
for dermatologists. The efficacy of this agent has 
been proved in a large controlled clinical trial but real 
world experience data is needed to corroborate it in 
clinical practice.
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